Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca lung cancer drug advances to phase III
The study will investigate the addition of Zactima (generic name vandetanib) to pemetrexed as second line treatment for patients with locally advanced or metastatic non-small cell lung cancer
The study will investigate the addition of Zactima (generic name vandetanib) to pemetrexed as second line treatment for patients with locally advanced or metastatic non-small cell lung cancer
The collaboration will focus on Adnectin-based therapeutics. Adnectins are based on human fibronectin, an extracellular protein that is naturally abundant in human serum. Adnectins are designed using the
“While prostate cancer growth is driven by androgens like testosterone, current anti-androgen therapies do not stop the growth of hormone-refractory prostate tumors. “These preclinical findings with MDV3100 are
The study involved four groups of eight rats, each group receiving a different level of black soya in their diet. The group that received the highest level of
The trial is being conducted by Merck and its US affiliate EMD Pharmaceuticals pursuant to the terms of a collaboration. Merck obtained the exclusive worldwide licensing rights for
The safety and efficacy of Cymbalta in the treatment of generalized anxiety disorder (GAD) was established in three studies in non-depressed adults with GAD. In all studies, Cymbalta
The results demonstrated a major response rate of 24% with a median overall survival at follow up of 8.5 months and a median time to progression of 3.5
Cobble is director of Canyons Medical Center in Sandy, Utah. Cobble is a primary care physician, board-certified lipidologist and certified hypertension specialist. Cobble succeeds James Ehrlich, M.D., who
This adjuvant trial will compare the effectiveness of Tykerb, also known as lapatinib, versus placebo given in high-risk patients following surgery. The design of this phase III trial
“Galderma fulfils all of our objectives: a strong commitment to the success of our botulinum toxin type A product in Europe and the maximization of its market penetration